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the median time to the ﬁrst MMF claim of the MMF group. A
multivariate logistic regression and a Wilcoxon test were
employed to assess risk of GI medication use and total medical
costs 1 year before and after occurrence of GI medication claim,
respectively. RESULTS: MMF was received by 173 (74%)
patients. GI medication use occurred in 139 (80%) of the
patients in the MMF group and in 29 (48%) of the patients in
the non-MMF group. Patients who received MMF were associ-
ated with a statistically signiﬁcant increase in risk of GI med-
ication use compared to patients who did not receive MMF (OR
= 7.65, p < 0.0001). Patients using GI medications generated sig-
niﬁcantly greater costs compared to patients not using GI med-
ications ($69,328 vs $48,301, p < 0.0001). CONCLUSIONS:
Heart transplant recipients who receive MMF had 7.7 times
greater risk of using GI medications compared to those who did
not receive MMF, which leads to increased costs.
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OBJECTIVE: To assess the economic consequences of changing
the prescription pattern of proton pump inhibitors (PPI) in
Sweden by use of a budget impact model (BIM). METHODS:
Data from published sources provided information about treat-
ment effects of different PPIs and productivity losses due to
upper gastrointestinal symptoms (GIS). Sale statistics at the
county council level and ofﬁcial Swedish price lists were used to
estimate drug costs. Data on wages ware taken from Statistics
Sweden and was used to estimate indirect costs. The BIM was
ﬂexible and allowed us to analyse (i) the drug budget impact in
a particular county council of switching between different PPIs
and (ii) the annual per patient drug cost and the indirect cost
from treating patients with different PPIs during a speciﬁc time
period. RESULTS: In the county council of Stockholm (1.9
million inhabitants) the annual PPI drug costs amount to about
€11.5 Million of which 50% and 14% comprise of generic
omeprazole and esomeprazole, respectively. The consequence of
switching from generic omeprazole to esomeprazole for 30% of
the patients would result in increasing the PPI drug costs by
11%. However, as the major part of the annual per patient costs
comprise of indirect costs due to productivity losses and absence
from work, esomeprazole only need to be 1–2 percent units more
effective in reducing GIS per week than generic omeprazole to
compensate for its higher price. CONCLUSION: The results
indicate the importance of including both direct and indirect
costs in BIMs when analyzing changes in drug prescription 
patterns.
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OBJECTIVES: Infection with Helicobacter pylori (HP) is asso-
ciated with several clinical conditions; the two most important
in both numbers and costs are peptic ulcer disease and gastric
cancer. In 1999 these two conditions were responsible for more
than 2000 deaths and €94.9 million of direct medical costs in
The Netherlands. A great step forward would be the develop-
ment of a preventive vaccine. The objective of this study is to
estimate the cost-effectiveness of a potential HP vaccine for The
Netherlands. METHODS: We designed a probabilistic Markov
model to fully incorporate the uncertainty associated with the
different transition probabilities. The model followed a birth
cohort during a period of 85 years. Transition probabilities for
the current situation without vaccination were based on Dutch
data. In presence of vaccination these probabilities were adjusted
using the attributive risks and vaccine efﬁcacy. Vaccine efﬁcacy
was assumed at 80% (range: 50–100). The perspective of the
analysis was that of the health care sector; only Dutch direct
medical costs were taken into account. For cost per dose we per-
formed different scenario analyses (base case: €50). For each 
scenario we conducted 10.000 Monte Carlo simulations. Cost-
effectiveness is expressed as net costs per life year gained (LYG)
where costs and effects were discounted according to the current
Dutch guidelines for pharmacoeconomic research (costs: 4%,
effects: 1.5%). RESULTS: For the base case scenario the median
cost-effectiveness ratio is estimated €2700 per LYG. For all sce-
narios investigated cost-effectiveness is estimated below the
informal Dutch threshold of €20,000 per LYG with a probabil-
ity of more than 0.95. CONCLUSIONS: According to our
model, for the greater part based on Dutch data, a potential new
developed HP vaccine could be considered cost-effective as the
cost-effectiveness is estimated below the informal Dutch thresh-
old used by decision makers.
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OBJECTIVES: A pentavalent rotavirus vaccine to prevent
rotavirus gastroenteritis (RVGE) in children will soon become
available. The objective of the study reported here was to assess
the health outcomes and the economic impact in the UK of a RV
vaccination programme vs no programme. METHODS: A birth
cohort was followed up to age 5 using a cohort model. Epi-
demiological parameters were taken from the REVEAL study (a
prospective epidemiological study conducted in the UK, 2004–
2005) and from literature. Costs were assessed from NHS and
societal perspectives by combining health care resource utiliza-
tion collected in REVEAL study and unit costs from ofﬁcial
sources. ITT effectiveness of the vaccine was taken from a large
worldwide clinical trial (70,000 children). Health outcomes
included home care cases, telephone consultations, GP/Acci-
dent&Emergency department visits, hospitalisations and noso-
comial infections. A sensitivity analysis was performed varying
the cost of the RV vaccine course between £80 and £100.
RESULTS: The model estimates that the introduction of a RV
vaccination programme with the pentavalent RV vaccine (90%
coverage rate) would reduce the RVGE burden by 75% in the
UK: 102,290 home care cases, 25,570 telephone consultations,
83,220 GP visits, 5660 Accident&Emergency department visits,
12,220 hospitalisations and 5040 nosocomial infections could be
avoided. The RVGE cost was estimated at £29m and £69m from
NHS and societal perspectives respectively. The introduction of
a RV vaccination programme would reduce the RVGE cost by
about 75% in both perspectives. For a vaccine course ranging
from £80 to £100, the RV vaccination programme is associated
with an incremental cost-effectiveness ratio that varies from
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£2460 to £3515 and from £0 to £1050 per hospitalization
averted from NHS and societal perspectives respectively. 
CONCLUSION: This study suggests that a RV vaccination pro-
gramme would have a substantial impact in reducing the impor-
tant burden of RVGE and associated costs in the UK.
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OBJECTIVES: Improved dissection techniques and sealing of the
resection surface with ﬁbrin glue are making a signiﬁcant con-
tribution to reduced blood loss in liver surgery. Fibrin glues are
available in the form of ﬁbrin-coated collagen ﬂeece patches that
are altered to suit the resected area, and also as a dual-compo-
nent spray application liquid glue. In this study we compared
both ﬁbrin glues for their differences in efﬁcacy, applicability and
costs. METHODS: In the last two years 200 elective liver resec-
tions were performed. This study focuses on the outcomes for
50 patients on whom either Tachocomb (Nycomed, Unter-
schleißheim) a ﬁbrin-coated collagen ﬂeece patch (Group 1, n =
25), or the spray application of Quixil (Ethicon, Norderstedt) a
ﬁbrin glue (Group 2, n = 25) were used intra-operatively. Demo-
graphic, operative, clinical data and cost were analyzed. In order
to ensure comparability in 2006 the calculation of the cost of the
ﬁbrin products was based on manufacturers currently valid price
lists and did not include discounts or VAT. RESULTS: Differ-
ences in number and weight of resected segments, transfusion
requirements, complications, ICU and hospital stay were not sta-
tistically different between groups. The average quantity of col-
lagen ﬂeece used for Group 1 was 76.6 ± 28.3 cm2. In Group 2,
the average amount of ﬁbrin glue used in the resected area was
2.4 ± 1 ml. A higher average cost for haemostatic agents per
patient was found in Group 1: 583.00 Euros versus 315.56 Euros
in Group 2 (p = 0.014). CONCLUSIONS: No signiﬁcant differ-
ence in the clinical outcome between groups was demonstrated.
Application of liquid ﬁbrin glue has a ﬁnancial advantage over
ﬁbrin-coated collagen ﬂeece patches, bearing in mind the impor-
tant role here of price agreements reached between individual
clinics and manufacturers.
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OBJECTIVES: To assess cost-effectiveness of esomeprazole 
40 mg once daily (od) versus generic omeprazole 20 mg od in 
the acute treatment of reﬂux esophagitis (RE) in Germany.
METHODS: A decision analysis model was used considering
pooled effectiveness data on 8 weeks treatment of RE from three
large, randomised, double-blind comparative clinical studies (n
= 4877). Results were analysed using an 8-week time horizon
and reported separately, including work productivity costs or
direct medical costs (drugs, physician contacts, investigations)
only. Utility values associated with having healed RE (0.84) or
unhealed RE (0.69) were derived from a survey (n = 1011) using
the rating scale method in patients with gastroesophageal reﬂux
disease (GERD). Estimates of GERD-related work productivity
loss (absence from work and reduced productivity while at work)
were derived from observed differences in productivity before
and after treatment with esomeprazole in an open-label clinical
study (n = 237). A probabilistic sensitivity analysis (PSA) on
direct medical costs was used to assess robustness of results,
along with additional analyses extending the time horizon
beyond 8 weeks. An acceptable threshold of €50,000 per quality-
adjusted life year (QALY) gained was used in the PSA. RESULTS:
When including direct medical costs only, the analysis resulted
in mean additional costs of around €13,000 per QALY gained
by using the more effective esomeprazole treatment strategy. The
PSA on the probability of esomeprazole treatment being below
a threshold of €50,000 per QALY gained supported robustness
of a conclusion that esomeprazole treatment is cost-effective
(incremental cost-effectiveness ratio <€50,000 threshold in 90%
of cases). When work productivity costs were included, results
indicated that the esomeprazole strategy is cost-saving. Extend-
ing the time horizon resulted in further cost-effectiveness advan-
tages for esomeprazole. CONCLUSIONS: Esomeprazole 40 mg
od is cost-effective compared with generic omeprazole 20 mg od
in the acute treatment of RE in Germany.
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OBJECTIVE: To determine the most cost-effective drug in the
treatment of bleeding esophageal varices within the formulary
available in the Mexican Institute of Social Security. METHODS:
Economic evaluation that used costs and quality of life infor-
mation from a multicentric clinical study in Mexican population
and an expert panel. Efﬁcacy data were obtained from a meta-
analysis. The alternatives included were terlipressin and
octreotide. The study perspective was institutional, 5 years time
horizon, 3% real discount rate for both effectiveness and costs.
Costs were estimated from ﬁnancial information from IMSS, and
are reported in US 2006 dollars. A decision tree with a Bayesian
approach, as well as a Markov model with four health states
describing the natural disease course and correction in the middle
of the cycle, were used in the analysis. Mean cost-utility rates,
net economic beneﬁts and net health beneﬁts were calculated.
The sensitivity analysis included threshold, one-way, scenarios
and probabilistic Monte Carlo simulation. RESULTS: Terli-
pressin had the lowest cost per QALY, $119,321 compared with
octreotide, $179,984. The number of QALYs was similar for
both alternatives, with a lower cost per QALY for terlipressin;
therefore, due its being the cheaper one, terlipressin was the
dominant alternative. The expected mean cost per patient in ﬁve
years of octreotide was $83,650, and $66,385 for terlipressin.
Acceptability curves showed that independently of WTP, terli-
pressin had a larger proportion of cost-utility cases in more than
70% and larger net economic and health beneﬁts compared with
octreotide. CONCLUSION: Terlipressin was the option with the
lower cost per QALY in the pharmacological treatment of bleed-
ing esophageal varices. Sensitivity analysis showed that the con-
clusions of the base study were robust.
